A Phase II study in patients with locally advanced pancreatic carcinoma: ARC-II- Akt-inhibition by Nelfinavir plus chemoradiation with gemcitabine and cisplatin.

Trial Profile

A Phase II study in patients with locally advanced pancreatic carcinoma: ARC-II- Akt-inhibition by Nelfinavir plus chemoradiation with gemcitabine and cisplatin.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2015

At a glance

  • Drugs Nelfinavir (Primary) ; Cisplatin; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jul 2015 Status changed from discontinued to completed as per European Clinical Trials Database record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jul 2012 Roche added as associations as reported in the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top